<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460324</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1157</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101157</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">As the COVID-19 pandemic becomes an endemic state, still many questions remain regarding the risks and impact of SARS-CoV-2 infection and vaccination in patients with immune-mediated inflammatory diseases (IMIDs) who were excluded from the phase 3 COVID-19 vaccination trials.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The BELCOMID study collected patient data and serological samples from a large, multicentric IMID patient cohort that was prospectively followed during sequential stages of the pandemic. Patients were stratified according to vaccination status into five groups across three sampling periods. Interactions between SARS-CoV-2 infection, COVID-19 vaccination status, IMID-treatment modalities and IMID course were explored.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 2165 patients with IBD, a dermatological or rheumatological IMID participated. SARS-CoV-2 infection rates increased over the course of the pandemic and were highest in IMID patients that had refused every vaccine. After baseline COVID-19 vaccination, serologic spike (S)-antibody responses were attenuated by particular types of immune-modulating treatment: anti-TNF, rituximab, JAKi, systemic steroids, combined biologic/immunomodulator treatment. Nonetheless, S-antibody concentration increased progressively in patients who received a booster vaccination, reaching 100% seroconversion rate in patients who had received two booster vaccines. Previous SARS-CoV-2 infection was found as a predictor of higher S-antibody response. Patients who had refused every vaccine showed the lowest rates of S-seroconversion (53.8%). Multiple logistic regression did not identify previous SARS-CoV-2 infection as a risk factor for IMID flare-up. Furthermore, no increased risk of IMID flare-up was found with booster vaccination.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Altogether, the BELCOMID study provides evidence for the efficacy and safety of COVID-19 vaccination and confirms the importance of repeated booster vaccination in IMID patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Geldof</LastName><ForeName>Jeroen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0126-2929</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truyens</LastName><ForeName>Marie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1264-4319</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabino</LastName><ForeName>João</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Research in Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrante</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Research in Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jo</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5303-9310</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lapeere</LastName><ForeName>Hilde</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hillary</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Laethem</LastName><ForeName>An</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Vlam</LastName><ForeName>Kurt</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verschueren</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0340-3580</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lobaton</LastName><ForeName>Triana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1817-7704</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padalko</LastName><ForeName>Elizaveta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Ghent University Hospital, 9000 Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vermeire</LastName><ForeName>Séverine</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9942-3019</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Research in Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IMID</Keyword><Keyword MajorTopicYN="N">booster</Keyword><Keyword MajorTopicYN="N">real world</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>Jeroen Geldof reports service as an advisory board member or speaker for Arena, Janssen, Celltrion, Abbvie, Viatris, Galapagos/Alfasigma and Takeda. Marie Truyens reports no conflicts of interest related to this project. João Sabino received speaker’s fees from Pfizer, Abbvie, Ferring, Falk, Takeda, Janssen, and Fresenius. JS received consultancy fees from Janssen, Ferring, Fresenius, Abbvie, Galapagos, Celltrion, Pharmacosmos, and Pharmanovia. Research support: Galapagos and Viatris. JS is supported by a Senior Clinical researcher grant from the Research foundation—Flanders. Marc Ferrante reports receipt of research grants from AbbVie, Biogen, EG, Janssen, Pfizer, Takeda and Viatris; consultancy fees from AbbVie, AgomAb Therapeutics, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, MRM Health, MSD, Pfizer, Takeda and ThermoFisher; and speakers’ fees from AbbVie, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen-Cilag, MSD, Pfizer, Takeda, Truvion Healthcare and Viatris. Jo Lambert has received recent grants/speaker fees of and performed consulting for AbbVie, Almirall, Bristol Myers Squibb, Celtrion, Janssen, Eli Lilly, Novartis, UCB Pharma—not personally, but paid to an institutional university account. Hilde Lapeere reports the following conflicts of interest: consultancy from AbbVie, Almirall, Leo Pharma, Eli Lilly, Celltrion, Novartis, Sanofi; speaker fees from Almirall, Leo Pharma, Eli Lilly, research funding from Pfizer. Tom Hillary reports the following conflicts of interest: consultancy from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Leo Pharma, Eli Lilly, Novartis, Sandoz, UCB Pharma, EG, Celltrion; speaker fees from AbbVie, Almirall, Amgen, Biogen, Celgene, Janssen, Leo Pharma, Eli Lilly, Novartis, Sanofi, UCB Pharma, Celltrion; research funding from AbbVie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Novartis, UCB Pharma, EG, Celltrion. An Van Laethem reports having received personal fees for participation on an advisory board, consultancy and/or as a speaker for Abbvie, Sanofi, Janssen, UCB, Novartis, Galderma. Kurt de Vlam reports being a consultant or speaker for Abbvie, Eli Lilly, Novartis, Pfizer, MSD, Acelyrin, UCB Pharma, Leo Pharma, Amgen and has received financial research support from UCB Pharma and Celgene. Patrick Verschueren reports having received research grants from Pfizer and Galapagos/AlfaSigma; consultancy fees from Pfizer, Galapagos, AlfaSigma, Lilly, Boehringer Ingelheim, Sidekick Health and Cytryl; speakers’ fees from Abbvie, Galapagos, Lilly, Roularta and Medicongress; and travel support from Fresenius Kabi and Abbvie. Triana Lobaton reports having received: (1) research grants from Abbvie, Mylan, MSD, Mundipharma, Biogen, Janssen, Pfizer, EG, Celltrion, Viatris Takeda; (2) speaker fees from Ferring, MSD, Abbvie, Janssen, Amgen, Fresenius Kabi, Alfasigma, Celltrion, Viatris and Takeda; (3) consultancy fees from Janssen, Galapagos, Alfasigma, Amgen, Bristol Myers Squibb Fresenius Kabi and Takeda. Elizaveta Padalko has received a consultant speaker’s fees/travel grants on institutional account from Hologic, bioMerieux, DiaSorin, Novosanis. Séverine Vermeire receives financial support for research from AbbVie, J&amp;J, Pfizer, Takeda and Galapagos; receives speakers’ and consultancy fees from AbbVie, Abivax, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Cytoki Pharma, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&amp;J, Lilly, Materia Prima, Mestag Therapeutics, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Surrozen, Takeda, Theravance, Tillots Pharma AG, VectivBio, Ventyx, Zealand Pharma. Séverine Vermeire holds a BOF-FKM from the KU Leuven.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460324</ArticleId><ArticleId IdType="pmc">PMC11510991</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101157</ArticleId><ArticleId IdType="pii">vaccines12101157</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Finckh A., Ciurea A., Raptis C.E., Rubbert-Roth A. Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients with Immune-Mediated Inflammatory Diseases. J. Infect. Dis. 2023;228:S13–S23. doi: 10.1093/infdis/jiad148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad148</ArticleId><ArticleId IdType="pmc">PMC10401619</ArticleId><ArticleId IdType="pubmed">37539758</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2019 IMID Collaborators Global, regional, and national incidence of six major immune-mediated inflammatory diseases: Findings from the global burden of disease study 2019. EClinicalMedicine. 2023;64:102193. doi: 10.1016/j.eclinm.2023.102193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102193</ArticleId><ArticleId IdType="pmc">PMC10507198</ArticleId><ArticleId IdType="pubmed">37731935</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C.-J., Wang Y.-K., Zhang S.-M., Ren M.-D., He S.-X. Global burden of inflammatory bowel disease 1990-2019: A systematic examination of the disease burden and twenty-year forecast. World J. Gastroenterol. 2023;29:5751–5767. doi: 10.3748/wjg.v29.i42.5751.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v29.i42.5751</ArticleId><ArticleId IdType="pmc">PMC10701338</ArticleId><ArticleId IdType="pubmed">38075848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy N.A., Jones G.-R., Lamb C.A., Appleby R., Arnott I., Beattie R.M., Bloom S., Brooks A.J., Cooney R., Dart R.J., et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020;69:984–990. doi: 10.1136/gutjnl-2020-321244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321244</ArticleId><ArticleId IdType="pmc">PMC7211081</ArticleId><ArticleId IdType="pubmed">32303607</ArticleId></ArticleIdList></Reference><Reference><Citation>Landewé R.B., Machado P.M., Kroon F., Bijlsma H.W., Burmester G.R., Carmona L., Combe B., Galli M., Gossec L., Iagnocco A., et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann. Rheum. Dis. 2020;79:851–858. doi: 10.1136/annrheumdis-2020-217877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217877</ArticleId><ArticleId IdType="pubmed">32503854</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A.M., Patel A., Subramanian S., Smith P.J. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: A pandemic-driven initiative. Lancet Gastroenterol. Hepatol. 2021;6:88–89. doi: 10.1016/S2468-1253(20)30392-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30392-7</ArticleId><ArticleId IdType="pubmed">33444534</ArticleId></ArticleIdList></Reference><Reference><Citation>Geldof J., Truyens M., Sabino J., Ferrante M., Lambert J., Lapeere H., Hillary T., Van Laethem A., de Vlam K., Verschueren P., et al. SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study—The BELCOMID study. Front. Immunol. 2023;14:1126351. doi: 10.3389/fimmu.2023.1126351.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1126351</ArticleId><ArticleId IdType="pmc">PMC10014825</ArticleId><ArticleId IdType="pubmed">36936974</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA  Letter of Authorisation: SARS-CoV-2 IgG 2020. Online Resource.  [(accessed on 20 September 2024)]; Available online:  https://www.fda.gov/media/137383/download.</Citation></Reference><Reference><Citation>Wadhwa A., Yin S., Freeman B., Hershow R.B., Killerby M., Yousaf A.R., Lester S., Mills L., Buono S.A., Pomeroy M., et al. Comparison of the SARS-CoV-2 spike protein ELISA and the Abbott Architect SARS-CoV-2 IgG nucleocapsid protein assays for detection of antibodies. PLoS ONE. 2021;16:e0255208. doi: 10.1371/journal.pone.0255208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255208</ArticleId><ArticleId IdType="pmc">PMC8320896</ArticleId><ArticleId IdType="pubmed">34324576</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Number of COVID-19 Deaths Reported to WHO (Cumulative Total). Online Resource.  [(accessed on 20 September 2024)].  Available online:  https://data.who.int/dashboards/covid19/deaths.</Citation></Reference><Reference><Citation>Akiyama S., Hamdeh S., Micic D., Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: A systematic review and meta-analysis. Ann. Rheum. Dis. 2021;80:384–391. doi: 10.1136/annrheumdis-2020-218946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218946</ArticleId><ArticleId IdType="pubmed">33051220</ArticleId></ArticleIdList></Reference><Reference><Citation>Eder L., Croxford R., Drucker A.M., Mendel A., Kuriya B., Touma Z., Johnson S.R., Cook R., Bernatsky S., Haroon N., et al. Understanding COVID-19 Risk in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Analysis of SARS–CoV-2 Testing. Arthritis Care Res. 2023;75:317–325. doi: 10.1002/acr.24781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24781</ArticleId><ArticleId IdType="pmc">PMC8653048</ArticleId><ArticleId IdType="pubmed">34486829</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcillán B., Salavert M., Regueiro J.R., Díaz-Castroverde S. Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review. Vaccines. 2022;10:297. doi: 10.3390/vaccines10020297.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10020297</ArticleId><ArticleId IdType="pmc">PMC8877652</ArticleId><ArticleId IdType="pubmed">35214755</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon D., Tascilar K., Kleyer A., Fagni F., Krönke G., Meder C., Dietrich P., Orlemann T., Kliem T., Mößner J., et al. Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS—CoV-2 in an Unvaccinated Cohort. Arthritis Rheumatol. 2022;74:783–790. doi: 10.1002/art.42035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42035</ArticleId><ArticleId IdType="pmc">PMC9011429</ArticleId><ArticleId IdType="pubmed">34951137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q., Mease P.J., Chiorean M., Iles-Shih L., Matos W.F., Baumgartner A., Molani S., Hwang Y.M., Belhu B., Ralevski A., et al. Machine learning to understand risks for severe COVID-19 outcomes: A retrospective cohort study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US health-care system. Lancet Digit. Health. 2024;6:e309–e322. doi: 10.1016/S2589-7500(24)00021-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(24)00021-9</ArticleId><ArticleId IdType="pmc">PMC11069366</ArticleId><ArticleId IdType="pubmed">38670740</ArticleId></ArticleIdList></Reference><Reference><Citation>Eder L., Croxford R., Drucker A.M., Mendel A., Kuriya B., Touma Z., Johnson S.R., Cook R., Bernatsky S., Haroon N., et al. COVID-19 Hospitalizations, Intensive Care Unit Stays, Ventilation, and Death Among Patients With Immune-mediated Inflammatory Diseases Compared to Controls. J. Rheumatol. 2022;49:523–530. doi: 10.3899/jrheum.211012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.211012</ArticleId><ArticleId IdType="pubmed">35105713</ArticleId></ArticleIdList></Reference><Reference><Citation>DiIorio M., Kennedy K., Liew J.W., Putman M.S., Sirotich E., Sattui S.E., Foster G., Harrison C., Larché M.J., Levine M., et al. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2022;8:e002587. doi: 10.1136/rmdopen-2022-002587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002587</ArticleId><ArticleId IdType="pmc">PMC9475962</ArticleId><ArticleId IdType="pubmed">36104117</ArticleId></ArticleIdList></Reference><Reference><Citation>Paik J. Ozanimod: A Review in Ulcerative Colitis. Drugs. 2022;82:1303–1313. doi: 10.1007/s40265-022-01762-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-022-01762-8</ArticleId><ArticleId IdType="pmc">PMC9499884</ArticleId><ArticleId IdType="pubmed">35994200</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon D., Tascilar K., Fagni F., Krönke G., Kleyer A., Meder C., Atreya R., Leppkes M., Kremer A.E., Ramming A., et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann. Rheum. Dis. 2021;80:1312–1316. doi: 10.1136/annrheumdis-2021-220461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220461</ArticleId><ArticleId IdType="pmc">PMC8103562</ArticleId><ArticleId IdType="pubmed">33958324</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakuraba A., Luna A., Micic D. Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. Gastroenterology. 2022;162:88–108.e9. doi: 10.1053/j.gastro.2021.09.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.09.055</ArticleId><ArticleId IdType="pmc">PMC8479970</ArticleId><ArticleId IdType="pubmed">34599933</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira Rezende R.P., Braz A.S., Guimarães M.F.B., Ribeiro S.L.E., Abreu Vieira R.M.R., Bica B.E., Cruz V.A., Libardi Lira Machado K.L., Carvalho J.S., Monticielo O.A., et al. Characteristics associated with COVID-19 vaccine hesitancy: A nationwide survey of 1000 patients with immune-mediated inflammatory diseases. Vaccine. 2021;39:6454–6459. doi: 10.1016/j.vaccine.2021.09.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.09.057</ArticleId><ArticleId IdType="pmc">PMC8463330</ArticleId><ArticleId IdType="pubmed">34600751</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahalyants V., Murphy W.S., Klebanov N., Lu C., Theodosakis N., Klevens R.M., Estir H., Lilly E., Asgari M., Semenov Y.R. Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts. J. Am. Acad. Dermatol. 2022;86:252–255. doi: 10.1016/j.jaad.2021.08.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2021.08.065</ArticleId><ArticleId IdType="pmc">PMC8428982</ArticleId><ArticleId IdType="pubmed">34509536</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner E.J., Ungaro R.C., Gearry R.B., Kaplan G.G., Kissous-Hunt M., Lewis J.D., Ng S.C., Rahier J.-F., Reinisch W., Ruemmele F.M., et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020;159:481–491.e3. doi: 10.1053/j.gastro.2020.05.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.032</ArticleId><ArticleId IdType="pmc">PMC7233252</ArticleId><ArticleId IdType="pubmed">32425234</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques C.D.L., Kakehasi A.M., Pinheiro M.M., Mota L.M.H., Albuquerque C.P., Silva C.R., Santos G.P.J., Reis-Neto E.T., Matos P., Devide G., et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: First results of ReumaCoV Brasil registry. RMD Open. 2021;7:e001461. doi: 10.1136/rmdopen-2020-001461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001461</ArticleId><ArticleId IdType="pmc">PMC7844930</ArticleId><ArticleId IdType="pubmed">33510041</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dam K.P.J., Volkers A.G., Wieske L., Stalman E.W., Kummer L.Y.L., van Kempen Z.L.E., Killestein J., Tas S.W., Boekel L., Wolbink G.J., et al. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: Long-term humoral immune responses and effects on disease activity. BMC Infect. Dis. 2023;23:332. doi: 10.1186/s12879-023-08298-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08298-6</ArticleId><ArticleId IdType="pmc">PMC10189216</ArticleId><ArticleId IdType="pubmed">37198536</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulze-Koops H., Krueger K., Vallbracht I., Hasseli R., Skapenko A. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann. Rheum. Dis. 2021;80:e67. doi: 10.1136/annrheumdis-2020-218075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218075</ArticleId><ArticleId IdType="pubmed">32591357</ArticleId></ArticleIdList></Reference><Reference><Citation>Melong Pianta Taleng C.M., Lauper K., Gilbert B., Cunningham T., Guemara R., Brulhart L., Dan D., Courvoisier D., Finckh A. Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab. RMD Open. 2021;7:e001711. doi: 10.1136/rmdopen-2021-001711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001711</ArticleId><ArticleId IdType="pmc">PMC8646967</ArticleId><ArticleId IdType="pubmed">34862310</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer-Gould A., Smith J.B., Li B.H. Multiple sclerosis, rituximab, and COVID-19. Ann. Clin. Transl. Neurol. 2021;8:938–943. doi: 10.1002/acn3.51342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51342</ArticleId><ArticleId IdType="pmc">PMC8045943</ArticleId><ArticleId IdType="pubmed">33783140</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M., Hyrich K.L., Al-Adely S., Carmona L., Danila M.I., Gossec L., Izadi Z., Jacobsohn L., Katz P., Lawson-Tovey S., et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 2020;79:859–866. doi: 10.1136/annrheumdis-2020-217871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Giollo A., Bertoldo E., Adami G., Cybulski A.J., Fassio A., Orsolini G., Idolazzi L., Gatti D., Viapiana O., Rossini M. Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than gluco. Ann. Rheum. Dis. 2022;81:e222. doi: 10.1136/annrheumdis-2020-218845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218845</ArticleId><ArticleId IdType="pubmed">32895237</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey A.R., Sobieszczyk M.E., Hirsch I., Sproule S., Robb M.L., Corey L., Neuzil K.M., Hahn W., Hunt J., Mulligan M.J., et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N. Engl. J. Med. 2021;385:2348–2360. doi: 10.1056/NEJMoa2105290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105290</ArticleId><ArticleId IdType="pmc">PMC8522798</ArticleId><ArticleId IdType="pubmed">34587382</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmahdi R., Ward D., Ernst M.T., Poulsen G., Hallas J., Pottegård A., Jess T. Impact of immunosuppressive therapy on SARS-CoV-2 mRNA vaccine effectiveness in patients with immune-mediated inflammatory diseases: A Danish nationwide cohort study. BMJ Open. 2024;14:e077408. doi: 10.1136/bmjopen-2023-077408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2023-077408</ArticleId><ArticleId IdType="pmc">PMC10882296</ArticleId><ArticleId IdType="pubmed">38387988</ArticleId></ArticleIdList></Reference><Reference><Citation>Jena A., James D., Singh A.K., Dutta U., Sebastian S., Sharma V. Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients with IBD: A Systematic Review and Meta-Analysis. Clin. Gastroenterol. Hepatol. 2022;20:1456–1479.e18. doi: 10.1016/j.cgh.2022.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2022.02.030</ArticleId><ArticleId IdType="pmc">PMC8856753</ArticleId><ArticleId IdType="pubmed">35189387</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander J.L., Kennedy N.A., Ibraheim H., Anandabaskaran S., Saifuddin A., Castro Seoane R., Liu Z., Nice R., Bewshea C., D’Mello A., et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): A multicentre, prospective, case-control study. Lancet Gastroenterol. Hepatol. 2022;7:342–352. doi: 10.1016/S2468-1253(22)00005-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(22)00005-X</ArticleId><ArticleId IdType="pmc">PMC8813209</ArticleId><ArticleId IdType="pubmed">35123676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy N.A., Lin S., Goodhand J.R., Chanchlani N., Hamilton B., Bewshea C., Nice R., Chee D., Cummings J.F., Fraser A., et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70:1884–1893. doi: 10.1136/gutjnl-2021-324789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324789</ArticleId><ArticleId IdType="pubmed">33903149</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y., Mandel M., Bar-On Y.M., Bodenheimer O., Freedman L.S., Ash N., Alroy-Preis S., Huppert A., Milo R. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N. Engl. J. Med. 2022;386:2201–2212. doi: 10.1056/NEJMoa2118946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118946</ArticleId><ArticleId IdType="pmc">PMC9165562</ArticleId><ArticleId IdType="pubmed">35613036</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmecht S., Tashkeev A., El Moussaoui M., Marechal N., Perée H., Tokunaga Y., Fombellida-Lopez C., Polese B., Legrand C., Wéry M., et al. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Front. Immunol. 2022;13:863554. doi: 10.3389/fimmu.2022.863554.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.863554</ArticleId><ArticleId IdType="pmc">PMC9195074</ArticleId><ArticleId IdType="pubmed">35711445</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayam R.M., Law J.C., Goetgebuer R.L., Chao G.Y.C., Abe K.T., Sutton M., Finkelstein N., Stempak J.M., Pereira D., Croitoru D., et al. Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases. JCI Insight. 2022;7:e159721. doi: 10.1172/jci.insight.159721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.159721</ArticleId><ArticleId IdType="pmc">PMC9220925</ArticleId><ArticleId IdType="pubmed">35471956</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowdish D.M.E., Chandran V., Hitchon C.A., Kaplan G.G., Avina-Zubieta J.A., Fortin P.R., Larché M.J., Boire G., Gingras A.-C., Dayam R.M., et al. When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study. J. Rheumatol. 2024;51:721–727. doi: 10.3899/jrheum.2023-1214.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.2023-1214</ArticleId><ArticleId IdType="pubmed">38621797</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen I.E., Jyssum I., Tveter A.T., Sexton J., Tran T.T., Mjaaland S., Kro G.B., Kvien T.K., Warren D.J., Jahnsen J., et al. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—A prospective cohort study. BMC Med. 2022;20:378. doi: 10.1186/s12916-022-02587-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02587-8</ArticleId><ArticleId IdType="pmc">PMC9534475</ArticleId><ArticleId IdType="pubmed">36199139</ArticleId></ArticleIdList></Reference><Reference><Citation>Syversen S.W., Jyssum I., Tveter A.T., Sexton J., Christensen I.E., Tran T.T., Bjørlykke K.H., Mjaaland S., Warren D.J., Kvien T.K., et al. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy. RMD Open. 2022;8:e002417. doi: 10.1136/rmdopen-2022-002417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002417</ArticleId><ArticleId IdType="pmc">PMC9638754</ArticleId><ArticleId IdType="pubmed">36328399</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy N.A., Goodhand J.R., Bewshea C., Nice R., Chee D., Lin S., Chanchlani N., Butterworth J., Cooney R., Croft N.M., et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021;70:865–875. doi: 10.1136/gutjnl-2021-324388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324388</ArticleId><ArticleId IdType="pubmed">33753421</ArticleId></ArticleIdList></Reference><Reference><Citation>Jena A., Mishra S., Deepak P., Kumar-M P., Sharma A., Patel Y.I., Kennedy N.A., Kim A.H.J., Sharma V., Sebastian S. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmun. Rev. 2022;21:102927. doi: 10.1016/j.autrev.2021.102927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102927</ArticleId><ArticleId IdType="pmc">PMC8404391</ArticleId><ArticleId IdType="pubmed">34474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung M.W., Dayam R.M., Shapiro J.R., Law J.C., Chao G.Y.C., Pereira D., Goetgebuer R.L., Croitoru D., Stempak J.M., Acheampong L., et al. Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases. J. Immunol. 2023;211:351–364. doi: 10.4049/jimmunol.2300190.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2300190</ArticleId><ArticleId IdType="pmc">PMC10352588</ArticleId><ArticleId IdType="pubmed">37326480</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Cirera S., Calvet J., Delgado de la Poza J.F., Berenguer-Llergo A., Orellana C., Rusiñol M., Llop M., Arévalo M., Garcia-Pinilla A., Costa E., et al. Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases. Eur. J. Med. Res. 2024;29:28. doi: 10.1186/s40001-023-01620-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-023-01620-7</ArticleId><ArticleId IdType="pmc">PMC10768211</ArticleId><ArticleId IdType="pubmed">38183092</ArticleId></ArticleIdList></Reference><Reference><Citation>Deepak P., Kim W., Paley M.A., Yang M., Carvidi A.B., Demissie E.G., El-Qunni A.A., Haile A., Huang K., Kinnett B., et al. Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2. Ann. Intern. Med. 2021;174:1572–1585. doi: 10.7326/M21-1757.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-1757</ArticleId><ArticleId IdType="pmc">PMC8407518</ArticleId><ArticleId IdType="pubmed">34461029</ArticleId></ArticleIdList></Reference><Reference><Citation>Bin Lee A.R.Y., Wong S.Y., Tay S.H. Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety. Vaccines. 2022;10:668. doi: 10.3390/vaccines10050668.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050668</ArticleId><ArticleId IdType="pmc">PMC9144569</ArticleId><ArticleId IdType="pubmed">35632424</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelman M.D., Weaver K.N., Zhang X., Dai X., Watkins R., Adler J., Dubinsky M.C., Kastl A., Bousvaros A., Strople J.A., et al. Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases. Am. J. Gastroenterol. 2022;117:462–469. doi: 10.14309/ajg.0000000000001619.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001619</ArticleId><ArticleId IdType="pubmed">35029167</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S., Kennedy N.A., Saifuddin A., Sandoval D.M., Reynolds C.J., Seoane R.C., Kottoor S.H., Pieper F.P., Lin K.-M., Butler D.K., et al. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat. Commun. 2022;13:1379. doi: 10.1038/s41467-022-28517-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28517-z</ArticleId><ArticleId IdType="pmc">PMC8927425</ArticleId><ArticleId IdType="pubmed">35296643</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak D., Kartnig F., Sieghart D., Simader E., Radner H., Mandl P., Göschl L., Hofer P., Deimel T., Gessl I., et al. Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases. J. Autoimmun. 2023;135:102981. doi: 10.1016/j.jaut.2022.102981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102981</ArticleId><ArticleId IdType="pmc">PMC9771756</ArticleId><ArticleId IdType="pubmed">36706534</ArticleId></ArticleIdList></Reference><Reference><Citation>Costanzo G.A.M.L., Sanna G., Pes F., Deiana C.M., Ledda A.G., Perra A., Palmas V., Manca V., Miglianti M., Coghe F., et al. The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study. Pathogens. 2024;13:506. doi: 10.3390/pathogens13060506.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens13060506</ArticleId><ArticleId IdType="pmc">PMC11206661</ArticleId><ArticleId IdType="pubmed">38921803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Planas D., Ouedrani A., Buffier S., Delage L., Nguyen Y., Bruel T., Stolzenberg M.-C., Staropoli I., Ermak N., et al. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Ann. Rheum. Dis. 2022;81:720–728. doi: 10.1136/annrheumdis-2021-221508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221508</ArticleId><ArticleId IdType="pubmed">35022159</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran A.P., Tassone D., Nossent J., Ding N.S. Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE) RMD Open. 2022;8:e002301. doi: 10.1136/rmdopen-2022-002301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002301</ArticleId><ArticleId IdType="pmc">PMC9114315</ArticleId><ArticleId IdType="pubmed">35577478</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.Y., Mao T., Klein J., Dai Y., Huck J.D., Jaycox J.R., Liu F., Zhou T., Israelow B., Wong P., et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283–288. doi: 10.1038/s41586-021-03631-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed U., Subramanian A., Wraith D.C., Lord J.M., McGee K., Ghokale K., Nirantharakumar K., Haroon S. Incidence of immune-mediated inflammatory diseases following COVID-19: A matched cohort study in UK primary care. BMC Med. 2023;21:363. doi: 10.1186/s12916-023-03049-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-023-03049-5</ArticleId><ArticleId IdType="pmc">PMC10512476</ArticleId><ArticleId IdType="pubmed">37735654</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A., Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N. Engl. J. Med. 2021;384:2092–2101. doi: 10.1056/NEJMoa2104840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104840</ArticleId><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Carubbi F., Alunno A., Santilli J., Natali L., Mancini B., Di Gregorio N., Del Pinto R., Viscido A., Grassi D., Ferri C. Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: New diagnoses and disease flares. RMD Open. 2022;8:e002460. doi: 10.1136/rmdopen-2022-002460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002460</ArticleId><ArticleId IdType="pmc">PMC9453424</ArticleId><ArticleId IdType="pubmed">36282905</ArticleId></ArticleIdList></Reference><Reference><Citation>Syversen S.W., Jyssum I., Tveter A.T., Tran T.T., Sexton J., Provan S.A., Mjaaland S., Warren D.J., Kvien T.K., Grødeland G., et al. Immunogenicity and Safety of Standard and Third-Dose SARS—CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy. Arthritis Rheumatol. 2022;74:1321–1332. doi: 10.1002/art.42153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42153</ArticleId><ArticleId IdType="pmc">PMC9347774</ArticleId><ArticleId IdType="pubmed">35507355</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado P.M., Schäfer M., Mahil S.K., Liew J., Gossec L., Dand N., Pfeil A., Strangfeld A., Regierer A.C., Fautrel B., et al. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: Data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. Ann. Rheum. Dis. 2023;82:698–709. doi: 10.1136/ard-2022-223499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-223499</ArticleId><ArticleId IdType="pmc">PMC10176347</ArticleId><ArticleId IdType="pubmed">36787993</ArticleId></ArticleIdList></Reference><Reference><Citation>Rider L.G., Parks C.G., Wilkerson J., Schiffenbauer A.I., Kwok R.K., Noroozi Farhadi P., Nazir S., Ritter R., Sirotich E., Kennedy K., et al. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: Results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology. 2022;61:SI143–SI150. doi: 10.1093/rheumatology/keac249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac249</ArticleId><ArticleId IdType="pmc">PMC9248066</ArticleId><ArticleId IdType="pubmed">35460240</ArticleId></ArticleIdList></Reference><Reference><Citation>Long M.D., Weaver K.N., Zhang X., Chun K., Kappelman M.D., PREVENT-COVID Study Group Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases. Clin. Gastroenterol. Hepatol. 2022;20:1881–1883.e1. doi: 10.1016/j.cgh.2022.01.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2022.01.056</ArticleId><ArticleId IdType="pmc">PMC8826602</ArticleId><ArticleId IdType="pubmed">35150924</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley S.F., Wei J., O’Donnell D., Stoesser N.E., Matthews P.C., Howarth A., Hatch S.B., Marsden B.D., Cox S., James T., et al. The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers. Clin. Infect. Dis. 2021;73:e699–e709. doi: 10.1093/cid/ciab004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab004</ArticleId><ArticleId IdType="pmc">PMC7929225</ArticleId><ArticleId IdType="pubmed">33400782</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieiro Santos C., Calleja Antolin S., Moriano Morales C., Garcia Herrero J., Diez Alvarez E., Ramos Ortega F., Ruiz de Morales J.G. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases. RMD Open. 2022;8:e001898. doi: 10.1136/rmdopen-2021-001898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001898</ArticleId><ArticleId IdType="pmc">PMC9065768</ArticleId><ArticleId IdType="pubmed">34987093</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E.G., Lustig Y., Cohen C., Fluss R., Indenbaum V., Amit S., Doolman R., Asraf K., Mendelson E., Ziv A., et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N. Engl. J. Med. 2021;385:e84. doi: 10.1056/NEJMoa2114583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan J.M., Mateus J., Kato Y., Hastie K.M., Yu E.D., Faliti C.E., Grifoni A., Ramirez S.I., Haupt S., Frazier A., et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. doi: 10.1126/science.abf4063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Tov A., Banon T., Chodick G., Kariv R., Assa A., Gazit S. BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients with Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign. Gastroenterology. 2021;161:1715–1717.e1. doi: 10.1053/j.gastro.2021.06.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.06.076</ArticleId><ArticleId IdType="pmc">PMC8252826</ArticleId><ArticleId IdType="pubmed">34224740</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan N., Mahmud N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications. Gastroenterology. 2021;161:827–836. doi: 10.1053/j.gastro.2021.05.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.05.044</ArticleId><ArticleId IdType="pmc">PMC8146263</ArticleId><ArticleId IdType="pubmed">34048782</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirasuthat S., Ratanapokasatit Y., Thadanipon K., Chanprapaph K. Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines among Patients with Immune-Mediated Dermatological Diseases: A Systematic Review and Meta-analysis. Acta Derm. Venereol. 2024;104:adv40009. doi: 10.2340/actadv.v104.40009.</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/actadv.v104.40009</ArticleId><ArticleId IdType="pmc">PMC11094464</ArticleId><ArticleId IdType="pubmed">38698654</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller A., Hancox J., Vedhara K., Card T., Mallen C., Van-Tam J.S.N., Abhishek A. Barriers and facilitators to vaccination uptake against COVID-19, influenza, and pneumococcal pneumonia in immunosuppressed adults with immune-mediated inflammatory diseases: A qualitative interview study during the COVID-19 pandemic. PLoS ONE. 2022;17:e0267769. doi: 10.1371/journal.pone.0267769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0267769</ArticleId><ArticleId IdType="pmc">PMC9462800</ArticleId><ArticleId IdType="pubmed">36084032</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>